GLP-1 Muscle Loss Meets Myostatin Blocking Therapy
A phase 2 trial suggests apitegromab may help preserve lean mass during tirzepatide weight loss, but larger studies are needed before this becomes routine obesity care.
A new phase 2 clinical trial found that adding apitegromab, an investigational antibody that blocks myostatin activation, helped adults taking tirzepatide lose less lean body mass while achieving similar total weight loss.
The finding matters because patients using GLP-1 and GLP-1/GIP medications often ask whether rapid weight loss means losing too much…
